A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5200 participants.
Also called NCT06008197
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,200 participants
- Registry
-
NCT06008197
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Germany, Greece, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Peru, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sri Lanka, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06008197. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-17 (actual); primary completion 2027-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- Acronym
- REDEFINE-HF
- Condition
- Heart Failure
- Condition
- Acute Heart Failure
- Intervention (Drug)
- Finerenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Colorado Prevention Center
- Collaborator
- St. Luke's Hospital, Kansas City, Missouri
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct06008197- Content hash
ab635baca6207cb99890776581ab129da0ea59cf9268298105159cc6e2f71f02